长春高新：公司拥有逾40种处于临床阶段或已提交新药临床试验（IND）申请的候选药物

Core Viewpoint - Changchun High-tech has over 40 candidate drugs in clinical stages or submitted for IND applications, with significant advancements in its pipeline expected by late 2025 [2] Group 1 - As of the last feasible date of the company's prospectus (late September 2025), it has more than 40 candidate drugs in clinical stages or submitted for IND applications [2] - Among these, there are 14 candidates in Phase III clinical trials or new drug application (NDA) stages, and 15 first-class innovative drugs [2] - The company advises stakeholders to refer to its subsequent annual reports for accurate disclosures by the end of 2025 and to check previous announcements for recent clinical progress of key innovative products [2]